Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 7:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kineret Clear all
Not yet recruiting Phase 1Phase 2 Interventional

Pre-emptive Anakinra for Cytokine Event Reduction

NCT06703216
View directory record Official record
Conditions
B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome, Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome
Interventions
Anakinra (Kineret®)
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

NCT03265132
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
Interventions
anakinra, Placebo
Biological · Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Results available

Anakinra for Inflammatory Pustular Skin Diseases

NCT01794117
View directory record Official record
Conditions
Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Jun 7, 2026, 7:47 AM EDT
Not yet recruiting Phase 1 Interventional

Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)

NCT07600190
View directory record Official record
Conditions
Asthma (Diagnosis), Persistent Asthma, Moderate Asthma Exacerbation
Interventions
Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Results available

Anti-Cytokine Therapy for Hemodialysis InflammatION

NCT03141983
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Anakinra, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension

NCT01479010
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Anakinra 100 mg subcutaneously daily
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Results available

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

NCT04432506
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jun 7, 2026, 7:47 AM EDT
Recruiting Phase 2 Interventional

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

NCT03587701
View directory record Official record
Conditions
Autoimmune Inner Ear Disease, Meniere's Disease
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 2 Interventional

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

NCT04205838
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Progressive Disease, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Fludarabine Phosphate
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Davis, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Results available

Anakinra as a Treatment for Hydradenitis Suppurativa

NCT01516749
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
anakinra
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 2 Interventional Results available

IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions

NCT02930122
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear
Interventions
anakinra (150mg), Saline intraarticularly
Drug · Other
Lead sponsor
Cale Jacobs, PhD
Other
Eligibility
14 Years to 40 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Not applicable Interventional Results available

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

NCT01542502
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease

NCT02179853
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Anakinra
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
1 Month to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Results available

Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)

NCT00897715
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2 Interventional Results available

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

NCT00635154
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
Anakinra (IL-1Ra), Dexamethasone acetate
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Jun 7, 2026, 7:47 AM EDT
Not yet recruiting Phase 3 Interventional

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

NCT07281027
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 7, 2026, 7:47 AM EDT
Withdrawn Phase 2 Interventional

Anakinra, COVID-19, Cytokine Storm

NCT04603742
View directory record Official record
Conditions
Covid19, Cytokine Storm, Mechanical Ventilation Complication
Interventions
Anakinra, 0.9% Saline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

NCT01950299
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Anakinra 100 mg, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 99 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 1 Interventional

Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene

NCT00072111
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
anakinra
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Acute Pericarditis With Anakinra

NCT03224585
View directory record Official record
Conditions
Acute Pericarditis
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Jun 7, 2026, 7:47 AM EDT
Recruiting Phase 2 Interventional

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

NCT04926467
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Anakinra
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss

NCT02414152
View directory record Official record
Conditions
Hearing Loss, Sudden
Interventions
anakinra
Drug
Lead sponsor
Andrea Vambutas
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jun 7, 2026, 7:47 AM EDT
Terminated Phase 1 Interventional

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

NCT02780583
View directory record Official record
Conditions
Macrophage Activation Syndrome
Interventions
kineret, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Jun 7, 2026, 7:47 AM EDT
Completed Phase 1 Interventional

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

NCT02021422
View directory record Official record
Conditions
Pancreas Cancer
Interventions
anakinra, Oxaliplatin, Irinotecan, fluorouracil
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 7, 2026, 7:47 AM EDT